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Screening for acquired cystic kidney disease: A decision analytic
perspective. Acquired cystic kidney disease (ACKD) increases the risk of
renal malignancy, and many authors suggest routine screening of dialysis
patients for ACKD and renal tumors. However, they have defined neither
the target population, the optimal screening strategy, the magnitude of its
benefit, nor its risk. We used decision analysis to evaluate strategies of
performing either computed tomography (CT) or ultrasound every three
years on all dialysis patients and annually on patients found to have cysts.
We compared these strategies to a strategy of seeking cysts and cancer
only if these are clinically suspected. The baseline analysis shows that both
CT and ultrasound may decrease cancer deaths by half for patients with a
life expectancy of 25 years. Screening for ACKD offers these patients as
much as a 1.6 year gain in life expectancy. However, for the majority of
patients beginning renal replacement therapy, age or comorbid disease
substantially limits life expectancy. For such patients, the gain in life
expectancy from an ACKD screening program is measured in days.
Sensitivity analyses show that the benefit of screening depends on the rate
of malignant transformation, which needs better definition. The gain in
life expectancy does not appear to be large enough to justify an ACKD
screening program for the entire ESRD population. However, for the
youngest and healthiest patients, a screening program would be of benefit.
The magnitude of this benefit is uncertain, because the analysis was
consistently biased in favor of the screening strategies.
Acquired cystic kidney disease (ACKD) is a common, and
worrisome, complication of end-stage renal disease (ESRD).
Although most cysts remain silent, ACKD can cause flank pain,
spontaneous hemorrhage and hematuria [1—3]. Its most feared
consequence, however, is renal cancer [4—7]. Several authors have
recommended CT or ultrasound surveillance of asymptomatic
dialysis patients after three years of renal failure and every one to
three years thereafter [4—6, 8—13]. However, neither the basis of
these recommendations nor their potential consequences have
been elaborated [14].
We used decision analysis to examine the consequences of CT
or ultrasound screening for ACKD and cancer. To represent the
natural history of ACKD-relatecl cancer, we constructed a tumor
growth model. Using data on renal cell carcinoma, we estimated
the relationship between tumor size, clinical stage and patient
survival. For each strategy, we calculated the number of deaths
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from ACKD-related cancer, the number of deaths from surgical
treatment, and patient life expectancy. Our analysis shows that the
benefit of screening for ACKD is much more limited than
generally presumed.
Methods
Decision analysis explicates the logic of a choice among alter-
nate strategies [15]. To analyze a decision, one defines possible
strategies, describes plausible and important clinical events asso-
ciated with each strategy, and specifies the probability of each
event. One estimates the value of each possible state of health
resulting from each strategy, and calculates the average expected
value of pursuing each strategy. The axioms of decision analysis
dictate that the strategy with the greatest expected value is
preferred. We describe the structure of this analysis in general
below. The Appendix presents the decision model, the tumor
growth model, probabilities and calculations in detail.
The decision model
Figure 1 shows the decision model, which compares three
strategies. The square decision node on the left in Figure 1A
represents the choice among the strategies. Under the no screen-
ing strategy, no screening for ACKD is performed. However,
patients who develop symptomatic cysts and/or cancer undergo
CT imaging. Under the CT screening strategy, CT screening
occurs after three years of dialysis. Patients found to have cysts
undergo annual CT thereafter, and the entire population under-
goes CT every three years. Screening tests may or may not
correctly identify cysts and cancer. The ultrasound (US) screening
strategy follows the same scheme, but substitutes ultrasound for
CT.
After the initial choice among strategies, a Markov state
transition model determines the prognosis by simulating recurrent
chance events [16—20]. The use of Markov models is well estab-
lished in the medical literature in general, and in particular in the
study of renal disease and renal failure [21—26]. Patients' states of
health are represented as states of the Markov process. They are
shown as branches emanating from the Markov node, a rectangle
with circles connected by an arrow. All three strategies lead to the
same Markov states. However, under the no screening strategy,
the upper six Markov states lead to the no screening subtree,
represented by a diamond, while under CT screening and US
screening, these upper six Markov states lead to the screening
subtree. Subtrees are cascades of chance events, represented by
207
208 Sarasin et al: Screening for acquired cystic kidney disease
Die from cancer, age, and
dialysis-related causes
Survive
Die from age and
dial sis-related causes Dead
Survive Nephrectomy No Cancer
Fig. 1. A. The choice among strategies and the
Markov model. B. The no screening subtree. C.
The screening subtree. D. The diagnosed cancer
subtree.
solid circular nodes, occurring within one cycle of the Markov
process. Figure 1 B and C shows the no screening and screening
subtrees, respectively. Each subtree contains the diagnosed cancer
subtree, which is shown in Figure 1D. The next six states lead to
chance nodes, denoted by solid circles. The terminal nodes, shown
as rectangles, are states of health at the end of a single cycle of the
Markov process.
For each of the three different strategies, each member of a
cohort begins in a particular state of health and is followed over
time. The passage of time is modelled as a series of cycles. In the
baseline analysis, the cycles are one year long. During each cycle,
each cohort member may remain in the same state of health or
move to another. The process of moving from one state of health
to another is represented by the subtrees and by subsequent
chance nodes. The probability of moving to another state of
health is derived from the literature and from expert opinion. The
process continues until all members of the cohort have died. All
members of the cohort who are alive in a given year contribute to
the overall survival of the cohort. Thus, the simulation predicts the
life expectancy of the cohort.
The Appendix gives a detailed account of the Markov state
transitions. Briefly, all patients begin either in the well state or in
the undiagnosed cysts state. During each annual Markov cycle,
patients may die, with deaths occurring at a rate determined by
patient age on reaching ESRD. During each cycle, survivors may
develop ACKD, cysts may undergo malignant transformation,
patients free of ACKD may develop renal cancer, symptoms may
make cancer clinically evident, and surgical treatment of localized
cancer may result in death. Cancers which become clinically
evident are evaluated and treated within the same cycle.
Patients who are thought to have Robson stage I—Ill cancer
undergo bilateral radical nephrectomy. Patients who have stage
IV cancer receive supportive treatment, but no specific therapy
for the malignancy. Those surgical survivors who actually had
cancer, and all stage IV patients, are assigned a cancer stage-
specific excess mortality rate. A few patients who survive bilateral
nephrectomy did not have cancer. Their screening tests were
falsely positive for malignancy. They are henceforth protected
against developing cysts and cancer.
The tumor growth model
To represent the natural history of renal cell cancer, we
constructed a Gompertzian tumor growth model, an exponential
process limited by a progressive decrease in the growth rate as
tumor size increases [20, 72] (Appendix). Tumor doubling time
allows calculation of cell count, cell count predicts tumor mass,
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and tumor mass predicts tumor size at any point in time. Tumor
size determines both staging and the probability that the tumor
will be detected during any cycle of the model.
Utilities
This analysis considers outcomes from the patient's perspective.
We measure the number of deaths from cancer and from surgery,
and as years of survival. A patient's survival is the sum of the
number of years lived in each different state. We do not apply
quality adjustments to account for the short-term morbidity of
procedures or the long-term morbidity associated with cysts or
with cancer in various stages. Such adjustment could easily be
incorporated into the model. However, the effect of ACKD or
renal cell cancer on the quality of life in ESRD has not been
characterized well enough to make such adjustments reliable. Nor
does this analysis consider cost, although costs could be added for
the purpose of computing cost-effectiveness from the payor's
perspective.
Assumptions and sources of bias
The absence of published information required assumptions on
several points, and assumptions can bias a decision model. To
avoid overlooking a benefit of screening, we chose our assump-
tions so as to achieve a consistent bias in favor of the screening
strategies. Our assumptions are as follows:
1. Renal cell cancers in dialysis patients, whether ACKD-
related or not, behave like renal cell carcinomas in patients who
are not uremic.
2. Renal cell cancer growth is an exponential process.
3. CT and US examinations have no complications. This as-
sumption biases the analysis in favor of the screening strategies.
4. The specificity of CT and US in detecting cysts is 100%. This
assumption biases the analysis in favor of the screening strategies.
5. Cysts develop at a constant rate and undergo malignant
transformation at a constant rate.
6. Neither cysts nor cancers are discovered incidentally in the
investigation of symptoms unrelated to cancer. Since the oppor-
tunity for incidental diagnosis under the no screening strategy
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Variable
Baseline
value
Literature
range
%
ACKD development
Prevalence at ESRD 13 15—70
Annual incidence after ESRD 7
Annual cancer incidence
in presence of ACKD 0.9 0.5—7
in absence of ACKD 0.2
Annual renal cancer mortality rates
Stage I 1 0.5—3
Stage II 4.5 4—10
Stage III A 10 9—27
Stage III B 28 25—35
Stage IV 50 35—60
Probability of perioperative 2 0.5—6
mortality
Test characteristics
Sensitivity
renal mass < 3 cm in diameter
CT 94 80—100
ultrasound 80 50—100
renal mass > 3 cm in diameter
CT 100 80—100
ultrasound 100 80—100
renal cysts
CT 100 50—100
ultrasound 60 30—100
Specificity
renal masses, all sizes
CT 100 90—100
ultrasound 100 90—100
cysts
CT 100 90—100
ultrasound 100 90—100
would diminish the benefit of screening, this assumption biases
the analysis in favor of the screening strategies.
7. The probability that a renal cancer is in any given clinical
stage is a linear function of the size of the tumor at that time. The
mean diameter of tumors less than 5 cm in diameter at diagnosis
is 2.5 cm, and the mean diameter of tumors greater than 5 cm in
diameter is 10 cm. The Appendix shows how these assumptions
allow estimation of stage distribution from data published on
tumor size and stage at diagnosis.
8. Bilateral nephrectomy mortality is low and constant across
different dialysis populations and across different age groups. This
assumption biases the analysis in favor of the screening strategies.
Summaiy of the data employed
Probabilities and rates used in the baseline analysis. Table 1 and
Figure 2 show the probabilities and rates used in the baseline
analysis. The Appendix explains these values.
Epidemiology ofACKD. ACKD is a bilateral condition, reported
in nearly every disease causing progressive renal insufficiency, and
found equally in patients treated by hemodialysis and by perito-
neal dialysis [4—9]. The disease can antedate the institution of
renal replacement therapy, and ACKD and ACKD-related tu-
mors can occur after transplantation [27]. Blacks appear to be
more commonly affected than Caucasians. Age at renal failure
does not appear to predispose to ACKD. Although one study
found that male sex predisposed to ACKD [86], other authors
found no difference between the sexes [4]. Cyclosporine has been
reported to accelerate the development of cysts in the native
kidneys of the recipients of cardiac as well as of renal allografts
[28, 29].
Estimates of the prevalence of ACKD in the dialysis population
range between 35% and 95%. A linear regression which we
performed on prevalence data in a review including 800 dialysis
patients [4] suggests that 13% of patients have ACKD when they
start dialysis. The probability that cysts are present increases by
7% every year; the regression has an r2 of 0.78.
Incidence of renal cancer in ACKD. In various studies, the
cumulative incidence of malignant transformation in ACKD
ranges from less than 1% to 7% [4—9, 30—341. In our baseline
analysis, we used the midpoint of a recent textbook estimate of the
cumulative incidence of renal carcinoma among ACKD: 3 to 6%
of patients with ACKD will develop cancer after a mean time on
dialysis of five years [35]. This implies an incidence of 0.9 cancers
per hundred patient-years.
Incidence of renal cancer in dialysis patients free of ACKD.
Dialysis patients free of ACKD are also at substantial risk of
developing renal carcinoma [36]. However, few of the studies
describing this relationship provide sufficient information to cal-
culate the rate at which the cancers appear. Glicklich et a! have
summarized 22 radiologic studies which specified the mean time
since ESRD [31]. Among 647 chronic dialysis patients, renal
neoplasms were found in four (0.6%). The mean follow-up was 3.4
years; we calculate the renal cancer incidence to have been 0.2
cancers per hundred patient-years.
Renal cancer: Clinical staging and mortality. Cancer classification
and survival data are taken from a non-uremic population with
clear cell renal carcinoma, because this histology predominates
among ACKD-related cancers [37]. We used the classification
introduced by Robson et a! and modified by Flocks and Kadesky,
which determines four clinical stages with different prognoses
[381.
Risks of nephrectomy. Published operative mortality rates for
patients who undergo radical nephrectomy for renal cancer
without metastasis range from 0.5 to 6% [39—421. However,
mortality may reach 10% among patients with metastatic disease
[43]. A recent review found the mean mortality in series of ESRD
Table 1. Rates and probabilities for baseline and sensitivity analyses 30
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Fig. 2. Life expectancy of ESRD patients as reported by the USRDS in 1993.
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patients undergoing general surgery to be 3.9% [4I. In our
baseline analysis, we used a perioperative mortality of 2%.
Imaging procedures. CT is considered more sensitive than
ultrasound in the diagnosis of ACKD, but both techniques appear
to be very accurate [45—49]. We found reports neither of CT or
US specificity in the diagnosis of cysts, nor of the sensitivity or the
specificity of either test in the diagnosis of renal cancer in the
presence of ACKD. We used information about healthy kidneys
to estimate test sensitivity for renal cancer. In our initial analysis,
we assumed that tests for cysts and renal cancer have perfect
specificity [50—52].
End-stage renal disease-related mortality. We used information
from the United States Renal Data System (USRDS) to estimate
average excess mortality in ESRD [53, 84]. The Appendix de-
scribes these calculations in detail. Age at ESRD and the cause of
ESRD significantly affect mortality rates among chronic dialysis
patients [54, 55]. Figure 2 shows the average life expectancy of
patients aged 20 to 80 who have survived the first 90 days of renal
replacement therapy. For a 20-year-old patient beginning treat-
ment for end-stage renal disease, average life expectancy is 25
years, while it is only five years for a 58-year-old patient, and 1.8
years for an 80-year-old [53]. We express our results as the benefit
of a screening program for incident ESRD patients at these three
ages. The median age of incident ESRD patients in the United
States between 1988 and 1991 was 62 years [56]. Therefore, the
five-year life expectancy of the hypothetical 58-year-old patient
exceeds the life expectancy of more than half the incident ESRD
population.
Results
Baseline analyses
The three panels of Figure 3 show results of the baseline
analyses for the entire range of life expectancies shown in Figure
2. For each strategy, Figure 3A shows the number of cancer
deaths in a hypothetical cohort of 10,000 patients, and Figure 3B
shows the number of nephrectomy deaths. Figure 3C shows the
gain in life expectancy if CT screening or US screening is used
rather than no screening.
For example, Figure 3A shows that in a hypothetical cohort of
10,000 20-year-old patients, with a life expectancy of 25 years,
treated according to the no screening strategy, 1337 will die of
cancer. CT screening decreases cancer deaths to 705. Using US
screening decreases cancer deaths to 785. However, Figure 3B
shows that the decrease in cancer deaths occurs at the cost of an
increase in surgical deaths, from 2 with no screening to 30 with US
screening and 33 with CT screening. The 2 surgical deaths with no
screening occur in patients whose cancers are discovered because
of symptoms.
Figure 3 A and B also shows that among 10,000 58-year-old
patients, with a life expectancy of five years, CT screening would
be associated with 41 deaths from cancer and 4 surgical deaths.
Using US screening would be associated with 52 deaths from
cancer and 3 surgical deaths, and no screening would be associ-
ated with 82 deaths from cancer and less than 1 surgical death.
Figure 3C shows how the screening strategies change life
expectancy. For 20-year-old patients with a life expectancy of 25
years, both CT screening and US screening increase life expect-
ancy by about 1.6 years compared to no screening, a prolongation
of approximately 6%. For 58-year-old patients with a life expect-
0
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Fig. 3. A. Number of cancer deaths predicted for the three strategies as a
function of age in a cohort of 10,000 patients. B. Number of surgical deaths
predicted for the three strategies as a function of age in a cohort of 10,000
patients. C. Gain in life expectancy (in months) from either screening
strategy, compared to no screening, as a function of age (in years).
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ancy of five years, CT and US screenings prolong average life
expectancy by 4 or 5 days, an 0.3% prolongation.
If all deaths could be expected to occur at the same time,
tabulation of deaths would be a reasonable measure by which to
compare strategies. However, surgical deaths occur early and
cancer deaths occur late. By contrast, life expectancy offers a
common denominator which allows a weighted combination of
the impact of early and late deaths, whether caused by tumor,
surgery or other medical problems. It is a more comprehensive
measure by which to compare strategies, and the standard metric
in studies exploring cancer screening strategies [57—61]. We base
subsequent sensitivity analysis and our conclusions on life expect-
ancy.
Sensitivity analysis
In sensitivity analysis (Fig. 4), we vary the value of parameters
over a wide range to determine (1) changes in life expectancy
associated with each strategy and (2) whether the ranking of
strategies changes. Because the two screening strategies have
similar outcomes, we display comparisons of no screening and CT
screening only. The last three sensitivity analyses described in the
text are not shown in Figures. These are analyses on CT specific-
ity, frequency of screening, and renal cell carcinoma doubling
time.
Annual rate of cyst development. Figure 4A shows the gain in life
expectancy associated with CT screening for different age groups
over a range of cyst development rates from half the baseline
(3.5%) to more than double the baseline rate (15%). CT screen-
ing remains the preferred strategy for all age groups. The gain in
life expectancy remains roughly the same for different cyst devel-
opment rates. Even if the rate of cyst development were 15%,
more than twice the baseline rate, and even if the higher rate is
applied to 20-year-old patients with an underlying life expectancy
of 25 years, the gain in life expectancy attributable to CT
screening would increase only by about one month compared to
the baseline calculations at a 7% cyst development rate, or by less
than 0.5% of life expectancy.
Cancer incidence. Figure 4B shows the effect of varying the
estimate of cancer incidence in ACKD. Screening is the preferred
strategy for all rates examined. The younger the patients and the
longer their life expectancy, the greater the sensitivity of the
analysis to the cancer incidence estimate. If cancer incidence is
0.5% per year, lower than the baseline, the gain provided by CT
screening ranges from less than 2 hours to 12 months, depending
on life expectancy. If cancer incidence is higher (7% per year), the
gain provided by CT screening may reach five years for the
20-year-old patients whose life expectancy is 25 years.
Nephrectomy mortality. In the baseline analysis, we used a single
low value of 2% for perioperative mortality across different age
groups. Since surgical mortality increases with age, this assump-
tion biases the analysis in favor of the screening strategies. Figure
4C shows that the life expectancy gain is relatively insensitive to
plausible changes in the estimate of nephrectomy mortality.
Reducing the estimate of nephrectomy mortality to 1% has little
effect.
Specificity of CT as a test for cancer. In our baseline analysis, we
assume that neither CT or US is ever falsely positive; both are
assigned a specificity of 100%. This assumption strongly biases the
analysis in favor of screening. We examined the effect of a 10%
false positive rate of CT as a test for cancer in the presence of
cysts. Under these circumstances, screening would actually
shorten survival for those patients aged 64 and older, or almost
half the incident ESRD population. False-positive CT scans
would prompt incorrect cancer diagnoses, which would occasion
unnecessary surgery, sometimes resulting in deaths. This loss of
life would overwhelm the reduction in cancer mortality for those
aged 64 years and older.
Frequency of screening. Increasing the frequency of screening
should increase its benefit by revealing cancer at an earlier stage.
We performed sensitivity analysis on the screening frequency. If
dialysis patients undergo annual CT screening for cysts, and those
found to have cysts undergo CT screening for cancer every six
months, the gain provided by CT screening compared to no
screening almost doubles for 20-year-old patients with a 25 year
life expectancy, from 1.6 years or approximately 6% prolongation
to 2.6 years or approximately 11% prolongation of life. For
58-year-old patients with a life expectancy of five years, the higher
screening frequency has a negligible impact.
Renal cell carcinoma doubling time. Varying tumor doubling
time from its baseline value (50 days) to lower (25 days) or higher
values (75 days) changes survival slightly, but does not affect the
ranking of strategies or substantially change the gains provided by
screening.
Discussion
Regular screening for ACKD and ensuing malignancies among
dialysis patients should reduce the number of deaths from renal
cancer. This gain would be achieved at the cost of an increased
number of surgical deaths. Our analysis shows the magnitude of
those two effects, and how they jointly affect life expectancy. We
have applied our model to patients beginning dialysis over a wide
range of ages, with corresponding variability in life expectancies.
For twenty-year-old patients beginning dialysis, with an average
life expectancy of twenty-five years, both CT and US screenings
increase life expectancy by about 1.6 years compared to no
screening, a prolongation of approximately 6%. By way of com-
parison, one analysis of coronary heart disease showed that
cessation of tobacco use would be expected to lengthen a 35-year-
old's life by 2.3 years [62]. Regular breast cancer screening may
prolong the life of a 50-year-old woman by 2 months [611.
Strategies to screen for colorectal cancer have been estimated to
prolong the survival of an asymptomatic 50-year-old man at
average risk by 31 to 88 days [58]. Strategies to screen for cervical
cancer have been estimated to prolong the survival of an asymp-
tomatic average-risk woman by 94 to 99 days [57]. It is standard
practice to recommend that patients stop using tobacco, and to
screen for colorectal, cervical and breast cancers. When the
screening tests are applied to the youngest adult ESRD patients,
the benefit of the screening ACKID screening programs which we
explored appears to be comparable to the benefit of these
established interventions.
However, the results of this analysis would not support a policy
of screening all dialysis patients for ACKD. The benefit of
screening, as Figure 3C shows, depends critically on life expect-
ancy. For 58-year-old patients, beginning dialysis treatment with a
life expectancy of five years, CT screening and US screening
prolong average life expectancy by 4 or 5 days, a 0.3% prolonga-
tion. For yet older patients, the absolute and relative gains are
even smaller. It has not been established what absolute or relative
gain should be considered an important gain in life expectancy
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[60, 63]. However, we think it unlikely that most patients would
consider a gain of a few days important. In this context, it is
important to bear in mind our model's consistent analytic bias in
favor of the screening strategies; the estimates of benefit calcu-
lated from this model represent upper bounds.
Since the median age of patients beginning dialysis in the
United States is now 62 years [56], this analysis implies that for
more than half of the incident ESRD population, screening of
asymptomatic individuals for ACKD is unlikely to be of benefit.
As in the general population, some individuals beginning dialysis
treatment are much healthier than others of the same age, and can
be expected to survive much longer. Important prognostic factors
include the cause of renal failure, the burden of coexistent
diseases [64—66], treatment-related variables [67—70], and per-
haps general health and function [71]. It is obvious that not all
20-year-olds beginning dialysis have a life expectancy of 25 years.
For some, burdened with diabetes, it is much shorter [54]. For
others it must therefore be longer. Conversely, there must be
some patients in their late 50's and 60's who are otherwise so
healthy that their life expectancy is substantially longer than the
mean, and they might derive benefit from screening. Finally, there
are all the patients in the middle, those beginning dialysis
treatment in their fourth, fifth and early sixth decades. Will these
patients benefit from screening? What is their physiologic age?
Development of instruments to predict survival from readily
available clinical data will be essential in the application of this
model to clinical practice.
Sensitivity analysis identifies the rate of cancer development as
one factor which could have a major effect on the decision to
screen young and otherwise healthy patients. At the baseline value
for cancer development of 0.9% per year, CT screening lengthens
the life expectancy of 20-year-olds by about 1.6 years, or about
6%. Figure 4B shows that if the rate of cancer development were
70 80 7% per year, an almost tenfold increase over our baseline
estimate, a screening program would increase the life expectancy
of such young and otherwise healthy patients by almost five years,
about a 28% gain in life expectancy compared to no screening.
Figure 4B also shows that even such a dramatic change in the
cancer incidence estimate would not substantially change the
benefit of screening to patients beginning dialysis after their mid
fifties. However, it would materially increase the benefit to
patients in their fourth and fifth decades. More accurate measure-
ment of the rate at which cancer develops in ACKD is thus
essential to decision making in the care of those ESRD patients
who have the longest life expectancy.
This analysis also shows that for patients with the shortest life
expectancy, the false positive rate of CT or US as a test for cancer
in the presence of ACKD becomes important. There may be
considerable disagreement over the desirability of a strategy
which yields a very small gain in life expectancy. On the other
hand, a strategy which slightly shortens survival is unlikely to be
attractive. Using the baseline assumption of no false positive tests
for cancer, screening prolonged survival, if only slightly, for all
ages. However, if the false positive rate of CT as a test for cancer
in the presence of ACKD were 10%, screening would shorten
survival for patients aged 64 and older. We found no published
data regarding the specificity of imaging procedures as tests for
cancer in kidneys distorted by ACKD. However, a false positive
rate of 10% in routine clinical practice would not be implausible
in the context of published CT and US test characteristics for
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other clinical entities [20]. Under those circumstances, screening
would actually shorten the average survival of almost half of
incident ESRD patients in the United States.
In summary, this analysis does not support a policy of routine
screening of the entire ESRD population for acquired cystic
kidney disease and renal malignancy. The two variables which are
most important in the decision are overall life expectancy and
cancer incidence. Improved methods for predicting life expect-
ancy and more precise estimates of cancer incidence should allow
better definition of subgroups likely to benefit from screening.
Screening for acquired cystic kidney disease and cancer appears to
offer substantial benefit only among those patients having the
longest life expectancy. However, for most of the incident ESRD
population, any benefit would be negligible.
Appendix
This appendix explains (1) the structure of the decision tree and
Markov model, (2) the tumor growth model, and (3) data used in
the analysis.
I. The decision tree and the Markov model
The thirteen states of health (Fig. 1A) used in the Markov
model are described below: (1) well is the initial state for those
dialysis patients who do not have ACKD, and the state to which
those who have not suffered any adverse events return; (2) undx
cysts is a state for dialysis patients with undiagnosed ACKD who
do not have renal cell cancer; (3) dx cysts is the corresponding
state for patients with diagnosed ACKD; (4) no cysts-undx cancer
is a state for patients without ACKD who have developed
undiagnosed cancer; (5) undx cysts-undx cancer is a state for
dialysis patients with undiagnosed ACKD, and undiagnosed can-
cer. The undiagnosed cancer will increase in size from one time
cycle (1 year) to another according to the tumor growth model. To
represent 30 years of follow-up, we created 30 undx cysts-undx
cancer states. During each of the 30 years, tumor size is different.
(6) Dx cysts-undx cancer is the corresponding state for patients
with diagnosed ACKD. Undiagnosed cancer increases in size as
described above, and there are also 30 dx cysts-undx cancer states.
(7) Treated cancer stage i, treated cancer stage ii, treated cancer
stage iiia, and treated cancer stage iiib are states for dialysis
patients with diagnosed and surgically treated renal cancer stage
I to IIIB. (8) Cancer stage iv is the corresponding state for
patients with diagnosed renal cancer stage IV. These patients
receive supportive therapy only (see Assumptions). (9) Nephrec-
tomy-no cancer is a state for dialysis patients in whom an incorrect
diagnosis of renal cancer was made, and who have survived
unnecessary nephrectomy. (10) Dead contains patients who have
died from any cause.
Under all three strategies, 87% of patients enter the Markov
model in the well state, and 13% enter in the undx cysts state. A
logical expression denoted by a solid triangle determines whether
the screening or no screening subtree in Figure 1A is followed.
In the no screening subtree (Fig. 1B), the first circular node
represents the probability of death from age or dialysis-related
causes. This probability recurs in each cycle over the entire
simulation. Patients who die move to the dead state. In the same
cycle, survivors may develop cysts or remain well. Patients may
develop cancer whether or not they have ACKD. Patients with
cancer may become symptomatic; the diagnosis of cancer is made,
and patients enter the diagnosed cancer subtree. At the end of the
Tumor doubling time
Gompertzian growth curve
Cell count
Tumor mass
Tumor size
Stage I Stage II Stage III Stage IV
Fig. 5. The model of tumor growth on which clinical stage assignments at
diagnosis are based.
cycle, patients who have developed neither cysts nor cancer return
to the well state. Patients without cysts who have developed
asymptomatic cancer move or return to the no cysts -undx cancer
state. Patients with cysts but without cancer move or return to the
undx cysts state. Patients with cysts and undiagnosed cancer move
or return to the undx cysts - undx cancer state.
In the screening subtree (Fig. 1C), all patients undergo regular
screening by CT or ultrasound. As in the no screening subtree,
they may die from age and dialysis-related causes, or may survive.
Survivors may develop cysts. Whether or not they have ACKD, all
patients may develop cancer. Symptomatic cancer will lead pa-
tients to the diagnosed cancer subtree as above. In the absence of
cancer symptoms, classification of patients with cysts and cancer
(cancer screening tpos and cancer screening fneg) depends upon
the sensitivity of the imaging procedure. For patients with cysts
but without cancer, classification (cancer screening fpos and
cancer screening tneg) depends upon the specificity of the test.
Patients falsely diagnosed as having cancer are subjected to the
risk of surgical mortality. Survivors move to the nephrectomy-no
cancer state. Patients correctly classified as free of cancer move
into the dx cysts and undx cysts states depending on the sensitivity
of the imaging procedure for cysts. We assume that no false
positive diagnoses of cysts are made (see Assumptions).
In the diagnosed cancer subtree (Fig. 1D), patients are classi-
fied by tumor size as being in one of the states, stages i to iv (see
The tumor growth model and clinical staging). Patients in stages ito
iii have surgery (see Assumptions). If they survive surgery, or are
in stage iv, they move to treated cancer stage i, treated cancer
stage ii, treated cancer stage iii or cancer stage iv, where prognosis
is determined by the clinical stage.
II. The tumor growth model and clinical staging
To simulate the natural history of renal cancer, we constructed
a tumor growth model which applies Gompertzian kinetics to the
tumor doubling time (Fig. 5) [72, 73]. Doubling times have been
calculated for many tumors and range from more than 160 days
for carcinoma of the esophagus to less than 15 days for embryonal
carcinoma of the testis [73]. For clear cell carcinoma of the
kidney, tumor doubling time has been estimated to be 50 days
[71.
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Table 2. Prevalence of clinical stages at diagnosis and size distribution
for different clinical stages
Stage I II III IV
Prevalence of tumor stage at
time of diagnosis %
Prevalence of tumors < 5
25
67
15
31
29
25
31
20
cm in diameter %
Prevalence of tumors > 5 33 69 75 80
cm in diameter %
Data are from [831.
The Gompertz equation for the number of tumor cells is of the
((logI])*l1 — e
Cellcount(t) = e
form:
where Cellcount is the number of cells at time t. This number is a
function of the number of tumor cells when t approaches infinity,
also called the plateau size (VM), and a function of the number of
tumor cells at time zero (N0). M is a constant, set to 1012, this
number of cells representing a volume of 1,000 cm3 and a mass of
1 kg. N0 is calculated by setting cellcount to 1012 as t approaches
infinity, yielding 2.34 x 10—16. The rate is based on the threshold
of clinical detectability and is calculated to be 6.67 >< iO— for a
tumor doubling time of 50 days [75].
We calculate the volume that corresponds to a given number of
cells with the formula: Volume = Ceilcount X 1O, since io cells
correspond to a volume of 1 cm3. Tumor diameter in centimeters
is calculated from the tumor volume through the formula for the
volume of a sphere: diameter = (6x Volume/u) h/3 The model thus
uses doubling time to predict tumor size at any calendar time.
From size we predict clinical stage and hence prognosis.
Tumor size has been used to predict clinical staging in breast
and lung cancer [76—78]. For renal cancer, a relationship between
the size of the primary tumor and clinical stages has also been
suggested. Bell found that tumors smaller than 3 cm in diameter
have the lowest incidence of metastases (5%) [79]. Kay showed
that patient survival is inversely related to tumor size [80].
Fuhrman et al confirmed the relationship between metastases and
size: 48% of patients with tumors less than 5 cm had metastases,
and 60% with tumors larger than 5 cm [81]. Recently, Hermanek
et al published data on 872 cases of surgically treated renal cell
carcinoma [82]. They found a significant relationship between
tumor size and macroscopic venous invasion, Macroscopic venous
invasion was not found in patients with tumors less than 2.5 cm in
diameter, but was found in 9% of those with tumors between 2.5
cm and 5 cm, in 26% of those with tumors between 5 and 7.5 cm,
in 46% of those with tumors between 7.5 cm and 10 cm, and in
64% of those with tumors greater than 10 cm. Tumor size and
perinephric invasion also correlated.
Golimbu et al studied prognostic factors in a large cohort of
patients with renal cell carcinoma [831. He found that the
proportion of tumors larger than 5 cm in diameter increased with
the stage of the disease. Stage TV tumors were larger than 5 cm in
80% of cases, but 67% of stage I tumors were smaller than 5 cm
in diameter. Table 2 shows the distribution of clinical stages at
diagnosis and the size distribution for different clinical stages.
Knowing the distribution of clinical stages at diagnosis from the
same study, we used Bayesian revision to calculate the probability
that a patient whose tumor is less than 5 cm in diameter is in each
of the four different stages; we performed the same calculation for
a patient whose tumor is greater than 5 cm in diameter [15]. We
assumed that the mean size of tumors smaller than 5 cm was 2.5
cm, and that the mean size of tumors larger that 5 cm was 10 cm.
We assumed that the probability that a tumor is in any given
clinical stage is a linear function of size. Using linear regression,
we could then predict the stage distribution for any tumor size.
Figure 6 shows this distribution. For example, the model predicts
that 68% of patients with a 2.5 cm tumor will have limited disease
(stage I or II), and that 32% will have more extensive disease
(stages III and IV).
III. Probabilities used in the baseline analysis
Mortality rates. ESRD mortality was calculated from the most
recent data available from the USRDS [53]. Five year survival
data from day 91 to 5 years + 90 days for patients aged 5 to 84
years at the time of ESRD were used to calculate age-specific
mortality rates using the declining exponential approximation of
life expectancy (the DEALE) [84]. The DEALE allows calcula-
tion of the average annual mortality rate as —(ln S) t, where
is time at which the survival S is measured. Linear regression on
age of the logarithmic transformation of the mortality rates
showed that
p. =e'' * 0.05) — 43)
where p. is the annual mortality rate (the inverse of the life
expectancy) and age is the age at which the patient reached
ESRD. This regression has an r2 of 0.98.
Rate of cyst development. The correlation between the preva-
lence of cysts and the duration of ESRD has been confirmed in
various series, both imaging and autopsy [3, 6, 11, 12, 45]. Matson
reviewed the current prevalence of ACKD among 800 dialysis
patients studied by CTor US [4]. The mean time since ESRD was
4.8 years. We performed a simple linear regression on Matson's
data to calculate the annual increase in the prevalence of cysts to
be 7%. Figure 7 shows this relationship. According to this model,
one would predict that 13% of patients have cysts when dialysis
therapy is begun.
Probability that cysts will be diagnosed. The probability that
ACKD will be correctly diagnosed or excluded depends on the
test used. In the normal kidney, contrast-enhanced CT with a thin
section technique produces excellent resolution of renal contour
and is sensitive enough to detect cysts as small as 0.3 to 0.5 cm in
diameter [851. In ACKD, although cysts are multiple and may
attain sizes of 2.5 cm to 3 cm, most are less than 0.5 cm in maximal
dimension. Moreover, in patients with end-stage renal disease, the
kidneys are often fibrotic, inhomogeneous, and shrunken. How-
ever, these morphologic changes do not appear to affect CT
accuracy in detecting cysts, which is reported to be 100% [86].
In contrast to CT, ultrasound has difficulty resolving cysts less
than 1 cm in a small fibrotic kidney [87]. This difference is
important, because most cysts in ACKD are 0.5 cm or less in size.
In the one blinded prospective study which compared CT and US
in renal imaging of long-term dialysis patients, ACKD was
diagnosed in 59% of patients by CT. Among patients with ACKD
by CT, US detected cysts in only of individuals [88]. However,
this is a small series, and no "gold standard" was used. In our
baseline analysis, we used a sensitivity of 60% for US and 100%
for CT. Specificity is assumed to be perfect for both procedures.
0.5
S
—.5
—5*—s
p—
—5
 — — — — — — — — — — — —
— — — — —
0 I I I
Time elapsed on dialysis, years
Fig. 7. Linear regression of ACKD prevalence on time elapsed since ESRD,
as reported by Matson [4J.
Probability that cancer will develop
Several authors have compiled series of dialysis patients in an
attempt to estimate the incidence of ACKD and carcinoma [5, 32,
331. Gehrig et al combined data from 9 autopsy studies of 330
patients with ACKD and a mean dialysis time of 3.7 years [6]. A
total of 26 patients had some evidence of renal neoplasms.
Adenocarcinoma, when defined as a tumor greater than 2 to 3 cm
in diameter, was present in only four patients, with metastases in
two. The 22 tumors accounting for the difference were small
benign papillary adenomas. This study yields an estimated 0.3/100
patient-years incidence of adenocarcinoma in ACKD. MacDou-
gall et al found three cases of autopsy-proven renal adenocarci-
noma in their 185 chronic dialysis patients over a six year period,
representing an incidence of 0.27/100 patient-years [34]. Matson
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and Cohen found four well-documented cases of renal carcinoma
A in 289 patients with ACKD followed for a mean of 4.8 years. (4 is
the sum of the numerators of their Fig. 1). This represents an
incidence of 0.28/100 patient-years [4]. In our baseline analysis, we
used an estimate of 0.9 cancers/100 patient-years derived from an
expert's opinion [35]. It is higher than other reported estimates,
and represents another bias in favor of screening.
Detection of renal cancer by screening. The probability that
cancer will be diagnosed depends on tumor size, and on the
sensitivity of the imaging procedure used. Tumor size depends on
time (see the growth model above), and sensitivity depends on
tumor size. Our model considered 1 cm to be the threshold of
detectability, allowing no tumors smaller than that threshold to be
detected by CT or US.2 3 4 5 6 7 8 9 10 11 CT is more sensitive than US in detecting masses in a normal
kidney. Recent studies found US to have 80% sensitivity and CT
94% sensitivity in detecting pathologically proved renal cell
carcinoma 3 cm or less in size [50, 51, 52]. A blinded study
compared US and CT in detecting renal masses in normal-sized
functioning kidneys, and found that US identified 60% of CT-
detected lesions between 1 and 2 cm, 82% of CT-detected lesions
between 2 and 3 cm, and 85% of lesions 3 cm or more in diameter
[52]. Thus, CT is very sensitive in detecting renal masses and has
some margin of superiority over US. Unfortunately, no published
data confirm this superiority in patients with ACKD. In our
model, we assumed that above 3 cm, both CT and US have perfect
sensitivity.
There are no published data on the specificity of CT and US in
detecting renal cancer in a multicystic kidney. However, patients
with ACKD present a special problem: retention cysts or hemor-
rhagic cysts can be similar to hyperdense masses on CT, and can
make distinction from renal tumors impossible. We found no
reports of CT or US false-positive rates for renal cancer diagnosis.
In our baseline analysis, we assumed that CT and US are never
falsely positive.
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Detection of renal cancer without screening
We assumed that some patients with cancer will become
symptomatic and be diagnosed during each time period. To
calculate this probability, we used data from 872 symptomatic
patients who had not been screened and who presented with renal
cell carcinoma [82]. These data provide a probability distribution
of the size of the renal cancer at the time of presentation: 1% had
tumors < 2.5 cm, 16% had tumors 2.5—5.0 cm, 27% had tumors
5—7.5 cm, 25% had tumors 7.5—10 cm, and 29% had tumors> 10
cm in diameter. Our model, which keeps track of the tumor size
(see the growth model above), applies these proportions to
determine the number of patients in whom cancer becomes
clinically apparent over time.
Mortality rates: Diagnosed renal malignancy. Matson reviewed
reports of renal cancer in dialysis and transplant patients and
performed a life table analysis [41. Although these data are subject
to selection bias, they provide some insight into the natural history
of ACKD-related cancer. The 35% five-year survival rate is close
to that for renal cancer in a non-uremic population, for which a
recent estimate of five-year survival is 42% [89].
In a non-uremic population, the prognosis of renal cell carci-
noma depends on the size of the primary tumor and on the
presence or absence of venous and lymph node involvement and
metastasis [90, 91]. We employed the modified Robson classifica-
tion [38]. Using this classification, the five-year survival for renal
cell carcinoma with surgical treatment ranges between 67% and
95% for Stage I, and between 51% and 77% for Stage II [42, 92,
93, 94, 951. For patients with Stage III, the five-year survival
ranges from 42% to 58% without lymph node involvement (Stage
111-A) and between 18% and 24% if lymph nodes are invaded
(Stage 111-B) [42, 45, 92]. For patients with metastatic disease,
five-year survival remains between 0% and 18% [26, 27, 61, 96].
In our baseline analysis, we used data from a recent series
including more than 800 patients with renal cancer treated with
total nephrectomy [82]. Compared to comparably aged patients
without cancer, the relative five-year survival is 92% for stage I,
77% for stage II, 58% for stage III A, 24% for stage III B, and 8%
for stage IV. The annual disease specific excess mortality rate was
calculated using the declining exponential approximation of life
expectancy [84].
Mortality rates: Undiagnosed renal malignancy. Our model allows
for the circumstance that patients may die of undiagnosed cancer.
Using the average clinical stage distribution of renal cancer at
diagnosis, we calculated a weighted average to obtain the excess
mortality rate for undiagnosed renal cancer.
Surgical mortality. Radical nephrectomy became the treatment
of choice for renal cancer when reports were published showing
that it improved the surgical cure rate and survival compared to
simple nephrectomy. Published overall perioperative mortality for
patients undergoing nephrectomy for renal cancer ranges from
2% to 10% [40—43]. This wide variation is explained by the
inclusion of patients with localized disease and of patients with
distant metastasis for whom early mortality is higher. We found
no perioperative mortality data on dialysis patients undergoing
nephrectomy for cancer. In our baseline analysis, the value for
perioperative mortality is 2%, and this value remains constant for
different age and population subgroups. This baseline value is
probably an underestimate, since age, diabetes mellitus and
associated coronary artery disease raise dialysis patients' surgical
mortality [97, 98, 99, 100, 101, 102].
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